Arnold Foundation Will Retain Drug Pricing Focus As Health Care Agenda Grows
In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.
You may also be interested in...
Beyond ICER: Arnold Foundation Wants To Dig Deeper On R&D And Pricing
Arnold Foundation VP Mark Miller explains how research into “what it costs to bring a drug to market” could supplement existing efforts to determine how prescription drug prices line up with value.
ICER’s ‘Unsupported Price Increase’ Report Due This Fall
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
Celgene has been vilified in the political realm for excessive price increases, which hasn’t helped its stock performance over past year and a half.